Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Search

Page Path
HOME > Search
8 "Mesalamine"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
Statement
IBD
Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey
Julajak Limsrivilai, Allen Yu-hung Lai, Silvia T. H. Li, Murdani Abdullah, Raja Affendi Raja Ali, Satimai Aniwan, Hoang Huu Bui, Jen-Wei Chou, Ida Normiha Hilmi, Wee Chian Lim, Jose Sollano, Michelle Mui Hian Teo, Shu-Chen Wei, Wai Keung Leung
Intest Res 2025;23(2):117-128.   Published online January 6, 2025
DOI: https://doi.org/10.5217/ir.2024.00085
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice. A physician survey was conducted among inflammatory bowel disease specialists in 8 Asian territories to understand practices and preferences in ulcerative colitis management, focusing on the use of 5-ASA and concordance with guideline recommendations. Survey findings were validated by country experts in diverse healthcare settings. Subgroup analyses stratified data by income levels and treatment reimbursement status. Ninety-eight valid responses were received from inflammatory bowel disease specialists or gastroenterologists among 8 economic entities. Significant differences were found in clinical practices and treatment preferences for ulcerative colitis management among different income-level and government-subsidy groups. Survey results are summarized in 8 findings that illustrate trends in 5-ASA use and guideline implementation across Asian territories. This study emphasizes socioeconomic factors that impact the adoption of guideline recommendations in real-world practice. Our findings indicate an eclectic approach to guideline implementation across Asia, based on resource availability and feasibility of treatment goals.
  • 3,036 View
  • 176 Download
Close layer
Original Article
IBD
Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
Ramit Mahajan, Arshdeep Singh, Saurabh Kedia, Kirandeep Kaur, Vandana Midha, Pabitra Sahu, Varun Mehta, Dharmatma Singh, Namita Bansal, Khushdeep Dharni, Sandeep Kaushal, Vineet Ahuja, Ajit Sood
Intest Res 2022;20(1):64-71.   Published online February 3, 2021
DOI: https://doi.org/10.5217/ir.2020.00100
AbstractAbstract PDFPubReaderePub
Background/Aims
Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). Long-term use of biologics in developing countries is limited by high cost and frequent side effects. An optimal maintenance strategy in these patients needs to be established.
Methods
A retrospective analysis of maintenance of clinical remission with combination of azathioprine (AZA) and 5-aminosalicylates (5-ASA) in patients with severe steroidrefractory UC where IFX (5 mg/kg intravenously at weeks 0, 2, 6) had been used only as an induction therapy was done at 2 centers in India. Primary outcome was the proportion of patients maintaining corticosteroid-free sustained clinical remission (SCR) at the end of study period. Rates of relapse and cost of therapy were also analyzed.
Results
Of the 137 patients who received rescue IFX induction therapy, 77 (56.2%) achieved clinical remission (mean age 34.81 ± 13.32 years, 68.83% males, median follow-up 4 years, range 3 months to 6 years) and were included. Cumulative corticosteroid-free SCR was maintained in 68%, 59%, 42%, and 35% patients at 1, 2, 4, and 6 years respectively. Sixty-seven relapses were observed in 33 patients. Majority of the relapses (45/67, 67.16%) occurred within first 2 years of follow-up. Two relapses were managed with re-induction with IFX, one required colectomy, whereas all other responded to repeat course(s) of corticosteroids. Annual per capita maintenance therapy with 5-ASA and AZA was cheaper by US$ 4,526 compared to maintaining remission with IFX.
Conclusions
Clinical remission achieved with IFX induction therapy in severe steroid-refractory UC can be sustained over long time with a combination of AZA and 5-ASA.

Citations

Citations to this article as recorded by  
  • Effect of Ornithine α-Ketoglutarate on Intestinal Microbiota and Serum Inflammatory Cytokines in Dextran Sulfate Sodium Induced Colitis
    Tao Wang, Junquan Tian, Wenxuan Su, Fan Yang, Jie Yin, Qian Jiang, Yuying Li, Kang Yao, Tiejun Li, Yulong Yin
    Nutrients.2023; 15(11): 2476.     CrossRef
  • Management of Ulcerative Colitis: A Review of Indian Literature
    Santhosh Rajendran, Ratnakar Kini, K. Muthukumaran, I. Shubha, A. Chezhian, R. Murali
    Gastroenterology, Hepatology and Endoscopy Practice.2023; 3(4): 127.     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo
    Alexander Keith Turbayne, Miles Patrick Sparrow
    Digestive Diseases and Sciences.2022; 67(12): 5382.     CrossRef
  • Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia
    Madhura Balasubramaniam, Neilanjan Nandi, Tina Aswani-Omprakash, Shaji Sebastian, Vishal Sharma, Parakkal Deepak, Shrinivas Bishu, Neha D. Shah, Sumit Bhatia, Tauseef Ali, Sharan Khela, Kiran Peddi
    Gastroenterology.2022; 163(5): 1145.     CrossRef
  • Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
    Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
    Intestinal Research.2022; 20(4): 452.     CrossRef
  • Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia
    Madhura Balasubramaniam, Neilanjan Nandi, Tina Aswani-Omprakash, Shaji Sebastian, Vishal Sharma, Parakkal Deepak, Shrinivas Bishu, Neha D. Shah, Sumit Bhatia, Tauseef Ali, Sharan Khela, Kiran Peddi
    Clinical Gastroenterology and Hepatology.2022; 20(11): 2421.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 7,942 View
  • 457 Download
  • 7 Web of Science
  • 9 Crossref
Close layer
Review
Inflammatory bowel diseases
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh
Intest Res 2020;18(4):355-378.   Published online July 13, 2020
DOI: https://doi.org/10.5217/ir.2019.09176
AbstractAbstract PDFPubReaderePub
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.

Citations

Citations to this article as recorded by  
  • Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
    Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
    Intestinal Research.2025; 23(1): 37.     CrossRef
  • Effectiveness of Tofacitinib in Ulcerative Proctitis Compared to Left Sided Colitis and Pancolitis
    Arshdeep Singh, Ramit Mahajan, Vandana Midha, Kirandeep Kaur, Dharmatma Singh, Ramandeep Kaur, Shreya Garg, Kirti Arora, Namita Bansal, Ajit Sood
    Digestive Diseases and Sciences.2024; 69(4): 1389.     CrossRef
  • The impact of 5-aminosalicylates on the efficacy of mesenchymal stem cell therapy in a murine model of ulcerative colitis
    Huanhuan Chen, Huimin Wang, XiaoJing Xu, Ya'nan Hu, Jing Su, Dongdong Li, Zimu Li, Shixiang Feng, Jinming Liu, Huanxiang Zhang, Xiaoyan Wang
    International Immunopharmacology.2024; 134: 112255.     CrossRef
  • The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
    Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis
    Intestinal Research.2023; 21(1): 161.     CrossRef
  • Development of Novel pH-Sensitive Eudragit Coated Beads Containing Curcumin-Mesalamine Combination for Colon-Specific Drug Delivery
    Eman J. Heikal, Rashad M. Kaoud, Shadeed Gad, Hatem I. Mokhtar, Abdullah Alattar, Reem Alshaman, Sawsan A. Zaitone, Yasser M. Moustafa, Taha M. Hammady
    Gels.2023; 9(4): 264.     CrossRef
  • Consenso colombiano de la enfermedad inflamatoria intestinal pediátrica
    José Fernando Vera Chamorro, Claudia Sánchez Franco, Melquicedec Vargas Sandoval, Diana Victoria Mora Quintero, Juan Pablo Riveros López, Fernando Sarmiento Quintero, Catalina Ortiz-Piedrahita, Otto Gerardo Calderón-Guerrero, Hugo Laignelet, Claudia Lilia
    Revista colombiana de Gastroenterología.2023; 38(Supl No. 1): 1.     CrossRef
  • Clinical Features and Long-Term Outcomes of Paediatric-Onset Inflammatory Bowel Disease in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
    Sang Hyoung Park, Jong Pil Im, Hyunju Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Joo Sung Kim, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
    Journal of Crohn's and Colitis.2022; 16(2): 207.     CrossRef
  • Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment
    Nuan Wen, Na Zhao, Huixian Xu, Ying Zhao, Jian Ma
    Irish Journal of Medical Science (1971 -).2022; 191(5): 2105.     CrossRef
  • 5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis
    Hyo Yeop Song, Geom Seog Seo
    The Korean Journal of Gastroenterology.2022; 79(1): 31.     CrossRef
  • The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis
    Eun Ae Kang
    Gut and Liver.2022; 16(3): 487.     CrossRef
  • Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
    Jihye Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2022; 37(5): 895.     CrossRef
  • Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
    Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2022; 37(6): 1140.     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
    You Sun Kim
    Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 12,301 View
  • 370 Download
  • 14 Web of Science
  • 14 Crossref
Close layer
Original Articles
Inflammatory bowel diseases
Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
Intest Res 2019;17(3):349-356.   Published online February 8, 2019
DOI: https://doi.org/10.5217/ir.2018.00064
AbstractAbstract PDFPubReaderePub
Background/Aims
A once-daily (OD) regimen of 5-aminosalicylic acid (5-ASA) was easier to comply with than a divided daily (DD) regimen, and that treatment efficacy for ulcerative colitis (UC) was not affected by the dosing regimen. This study evaluated treatment adherence of OD and DD dosing in the Korean UC patients.
Methods
This study was a prospective, multicenter, randomized trial. UC patients were enrolled who have been in remission for more than 3 months. Patients were randomly assigned to the OD or DD group in a 1:1 ratio. The primary endpoint was adherence rate measured by tablet counts and self-reported adherence rate at 3, 6, 9, and 12 months. The relapse rate was measured at 1 year.
Results
Data from the 180 patients who were randomized were analyzed. Both self-reported adherence rate and adherence rate measured by tablet counts were not different at every points, including 1 year. The patients’ satisfaction of the OD group was higher than that of the DD group (P<0.001). At 1 year, 91.2% and 95.5% of patients in the OD group and DD group had maintained clinical remission, respectively (P=0.37).
Conclusions
The adherence rates were not different between the OD group and DD group. The patients’ satisfaction was higher in the OD group than in the DD group. 5-ASA OD dosing might have the same effect as DD for the maintenance of UC remission.

Citations

Citations to this article as recorded by  
  • Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis
    Cristiano Pagnini, Elisabetta Antonelli, Barbara Scrivo, Maria Cappello, Marco Soncini, Roberto Vassallo, Giammarco Mocci, Maria Carla Di Paolo
    Journal of Personalized Medicine.2025; 15(4): 123.     CrossRef
  • Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review
    Obreniokibo Amiesimaka, Kristina Aluzaite, Rhiannon Braund, Michael Schultz
    Patient Preference and Adherence.2024; Volume 18: 905.     CrossRef
  • Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
    Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
    Alimentary Pharmacology & Therapeutics.2024; 60(3): 389.     CrossRef
  • Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
    Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
    Journal of Coloproctology.2021; 41(01): 096.     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
    You Sun Kim
    Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
  • Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs
    Axel Dignass, John Waller, Joseph C. Cappelleri, Irene Modesto, Agnes Kisser, Lena Dietz, Marco DiBonaventura, Robert Wood, Melanie May, Berit Libutzki, Danielle Bargo
    Journal of Medical Economics.2020; 23(4): 415.     CrossRef
  • Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
    Alistair Murray, Tran M Nguyen, Claire E Parker, Brian G Feagan, John K MacDonald
    Cochrane Database of Systematic Reviews.2020;[Epub]     CrossRef
  • 8,943 View
  • 192 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
IBD
Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
Keiji Yagisawa, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Takahiko Toyonaga, Miki Miura, Mari Hayashida, Eiko Saito, Masaru Nakano, Hajime Matsubara, Tadakazu Hisamatsu, Toshifumi Hibi
Intest Res 2019;17(1):87-93.   Published online December 14, 2018
DOI: https://doi.org/10.5217/ir.2018.00078
Correction in: Intest Res 2020;18(3):343
AbstractAbstract PDFPubReaderePub
Background/Aims
Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The relative acceptabilities of these formulations may influence patient adherence; however, they have not been compared to date. This study aimed to evaluate the acceptabilities of the 2 formulations of CR mesalazine in relation to patient adherence using a crossover questionnaire survey.
Methods
UC patients were randomly assigned to 2 groups in a 1:1 ratio. Patients in each group took either 4 g of CR mesalazine tablets or granules for 6 to 9 weeks, and then switched to 4 g of the other formulation for a further 6 to 9 weeks. The acceptability and efficacy were evaluated by questionnaires, and adherence was assessed using a visual analog scale. The difference in acceptabilities between the 2 formulations and its impact on adherence were assessed.
Results
A total of 49 patients were prospectively enrolled and 33 patients were included in the analysis. Significantly more patients found the tablets to be less acceptable than the granules (76% vs. 33%, P=0.0005). The granules were preferable to the tablets when the 2 formulations were compared directly (73% vs. 21%, P=0.004), for their portability, size, and numbers of pills. The adherence rate was slightly better among patients taking the granules (94% vs. 91%) during the observation period, but the difference was not significant (P=0.139).
Conclusions
CR mesalazine granules are more acceptable than tablets, and may therefore be a better option for long-term medication.

Citations

Citations to this article as recorded by  
  • Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
    Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
    Intestinal Research.2025; 23(1): 37.     CrossRef
  • Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis
    Cristiano Pagnini, Elisabetta Antonelli, Barbara Scrivo, Maria Cappello, Marco Soncini, Roberto Vassallo, Giammarco Mocci, Maria Carla Di Paolo
    Journal of Personalized Medicine.2025; 15(4): 123.     CrossRef
  • Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
    Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
    Alimentary Pharmacology & Therapeutics.2024; 60(3): 389.     CrossRef
  • A review on taste masked multiparticulate dosage forms for paediatric
    Khater AL-Japairai, Samah Hamed Almurisi, Abd Almonem Doolaanea, Syed Mahmood, Fawaz Alheibshy, Ahmed Alobaida, Nadiya Abdul-Halim, Bappaditya Chatterjee
    International Journal of Pharmaceutics.2023; 632: 122571.     CrossRef
  • Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey
    Xavier Hébuterne, Stephan R Vavricka, Helen C Thorne, Lara MacKenzie-Smith, Raphaël Laoun, Johan Burisch
    Inflammatory Intestinal Diseases.2023; 8(1): 41.     CrossRef
  • Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis
    Xinyi Guo, Changxing Liu, Yahui Huang, Naeem Jan
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Factors Associated with Self-reported Medication Adherence in Japanese Community-dwelling Elderly Individuals: The Nakajima Study
    Natsuko Ishida, Yurina Tokumoto, Yukio Suga, Moeko Noguchi-Shinohara, Chiemi Abe, Sohshi Yuki-Nozaki, Ayaka Mori, Mai Horimoto, Koji Hayashi, Kazuo Iwasa, Masami Yokogawa, Mai Ishimiya, Hiroyuki Nakamura, Kiyonobu Komai, Ryo Matsushita, Junko Ishizaki, Ma
    YAKUGAKU ZASSHI.2021; 141(5): 751.     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
    You Sun Kim
    Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • Association of Self-Reported Medication Adherence with Potentially Inappropriate Medications in Elderly Patients: A Cross-Sectional Pilot Study
    Motoyasu Miyazaki, Masanobu Uchiyama, Yoshihiko Nakamura, Koichi Matsuo, Chika Ono, Miwa Goto, Ayako Unoki, Akio Nakashima, Osamu Imakyure
    International Journal of Environmental Research and Public Health.2020; 17(16): 5940.     CrossRef
  • Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
    Satoshi Tamura, Natsuki Ishida, Takahiro Miyazu, Shunya Onoue, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
    Scientific Reports.2020;[Epub]     CrossRef
  • 9,371 View
  • 354 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
IBD
Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy
Daisuke Saito, Mari Hayashida, Taro Sato, Shintaro Minowa, Osamu Ikezaki, Tatsuya Mitsui, Miki Miura, Akihito Sakuraba, Tadakazu Hisamatsu
Intest Res 2018;16(2):273-281.   Published online April 30, 2018
DOI: https://doi.org/10.5217/ir.2018.16.2.273
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Mesalazine is an effective drug for treating ulcerative colitis (UC), but causes allergic symptoms in a few cases. Therefore, the objective of this study was to evaluate the usefulness of the drug-induced lymphocyte stimulation test (DLST) for the diagnosis of mesalazine allergy.

Methods

Patients with UC treated with mesalazine with or without a history of associated adverse events (AEs) were enrolled at Kyorin University Hospital from July 2016 to April 2017.

Results

The DLST was performed in 104 patients with UC, of which 24 had a history of AEs due to mesalazine treatment. The control value of DLST was 337.4±296.3 counts per minute (cpm) in the AE+ group and 408.0±371.9 cpm in the AE− group. The measured value of DLST was 578.8±424.7 cpm in the AE+ group and 476.5±471.8 cpm in the AE− group. The stimulation index (SI) was 243.9%±291.1% in the AE+ group and 119.8%±53.0% in the AE− group. The SI value and DLST positivity were significantly higher in the AE+ group than in the AE− group (P=0.030 and P=0.029, respectively). The test sensitivity and specificity were 0.240 and 0.805, respectively, and the false-positive and false-negative rate was 0.195 and 0.760, respectively.

Conclusions

The DLST for mesalazine showed low sensitivity and high specificity, suggesting that it may be useful for the definitive diagnosis of allergy to mesalazine.

Citations

Citations to this article as recorded by  
  • A Case of Ulcerative Colitis with Acute Pericarditis after Dose Escalation of Mesalazine
    Jun Wada, Kazumasa Kawashima, Michio Onizawa, Naohiko Gunji, Yu Watahiki, Chiharu Sakuma, Mai Murakami, Tomoaki Mochimaru, Shunsuke Miura, Hiromasa Ohira
    Internal Medicine.2025;[Epub]     CrossRef
  • Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis
    Kenji Kinoshita, Shintaro Sawaguchi, Kai Toyoshima, Sonoe Yoshida, Takahiro Yamamura, Kosuke Nagai, Ikko Tanaka, Kazuteru Hatanaka, Yoshiya Yamamoto, Hirohito Naruse, Takehiko Katsurada, Naoya Sakamoto
    Gastroenterología y Hepatología.2025; : 502347.     CrossRef
  • Hydralazine‐Induced ANCA Vasculitis Presenting With Pericarditis: A Novel Case and Literature Review
    Ahmed Sami Hammami, Osejie Oriaifo, Sinda Hidri, Sukhvir Singh, Husam El Sharu, Joshua Peltz, Soroush Nomigolzar, Kunjan Udani, Aiden Abidov
    Case Reports in Cardiology.2025;[Epub]     CrossRef
  • Secondary loss‐of‐response associated with intolerance to Janus kinase inhibitor in a boy with ulcerative colitis
    Yuka Minoura, Koji Yokoyama, Yuko Okada, Shinya Fukuda, Hideki Kumagai
    Pediatrics International.2025;[Epub]     CrossRef
  • Tenapanor‒induced drug eruption in hemodialysis patient： A case report
    Hisato Shima, Hiroyoshi Nakatsuji, Manabu Sakaki, Yoshihide Murakami, Takumi Hamao
    Nihon Toseki Igakkai Zasshi.2025; 58(4): 215.     CrossRef
  • A Rare Case of Asymmetric Periorbital Edema due to Delayed Hypersensitivity Reaction to Thyroid Hormone Replacement
    Quynh Nguyen, Hoang V.K. Dinh, Vien Phan, Nguyet Nguyen, Quan Nguyen, Van Phan
    AACE Endocrinology and Diabetes.2025; 12(1): 50.     CrossRef
  • Cutaneous Adverse Events Following Nemolizumab Administration: A Review
    Yoshihito Mima, Masako Yamamoto, Ken Iozumi
    Journal of Clinical Medicine.2025; 14(9): 3026.     CrossRef
  • Drug-induced Interstitial Nephritis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
    Daichi Hayashi, Tsutomu Nishida, Naoto Osugi, Yasuo Kusunoki, Satoru Okabe, Yoshifumi Fujii, Dai Nakamatsu, Kengo Matsumoto, Masashi Yamamoto, Koji Fukui
    Internal Medicine.2024; 63(8): 1081.     CrossRef
  • Hemodialysis patients with allergic reactions to dialysate whose symptoms improved without dialysate change：Two case reports
    Hisato Shima, Yoko Nishiuchi, Yoshio Fukata, Takuya Okamoto, Manabu Tashiro, Tomoko Inoue, Hiroyasu Bando, Hiroyuki Azuma, Naohito Iwasaka, Takuji Ohara, Toshio Doi, Kazuyoshi Okada, Jun Minakuchi
    Nihon Toseki Igakkai Zasshi.2024; 57(1): 23.     CrossRef
  • Clinical Features of Thiopurine-Induced Acute Pancreatitis: Comparison Between Patients With and Without Inflammatory Bowel Disease
    Tomofumi Oizumi, Yosuke Toya, Shunichi Yanai, Takayuki Matsumoto
    Crohn's & Colitis 360.2024;[Epub]     CrossRef
  • Allergic clinical symptoms and distribution of stimulation index of drug lymphocyte stimulation test for local anesthetics
    Yukiko Baba, Yu Sato, Ken Takahashi, Takaya Ito, Ryo Wakita, Shigeru Maeda
    Oral and Maxillofacial Surgery.2024;[Epub]     CrossRef
  • Lymphocyte stimulation test for diagnosing hen’s egg yolk–induced enterocolitis syndrome
    Naoki Kajita, Go Kusakawa, Hiroki Seto, Keiko Hirao, Shoko Yokoyama, Emi Morikawa, Kumiko Morita, Masami Narita, Koichi Yoshida
    Journal of Allergy and Clinical Immunology: Global.2023; 2(4): 100138.     CrossRef
  • Risk factors for intolerance of oral 5‐aminosalicylic acid preparations in pediatric ulcerative colitis
    Naoki Abe, Naomi Iwata, Ryuhei Yasuoka, Daisuke Nishida, Asami Oohara, Haruna Nakaseko, Shiro Sugiura, Shinji Kawabe
    Pediatrics International.2023;[Epub]     CrossRef
  • Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies
    Subha Ghosh, Himanshu Deshwal, Rebecca Haraf, Shine Raju, Mnahi Bin Saeedan, Pralay Sarkar, Thomas Gildea, Carol F. Farver, Atul C. Mehta
    CHEST Pulmonary.2023; 1(3): 100018.     CrossRef
  • Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
    Yohei Mikami, Junya Tsunoda, Shohei Suzuki, Ichiro Mizushima, Hiroki Kiyohara, Takanori Kanai
    Digestion.2023; 104(1): 58.     CrossRef
  • The Forefront of Drug Therapy for Ulcerative Colitis
    Tadakazu Hisamatsu, Daisuke Saito, Minoru Matsuura
    Nippon Daicho Komonbyo Gakkai Zasshi.2023; 76(10): 580.     CrossRef
  • Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease
    Kaoru Suzuki, Yoichi Kakuta, Takeo Naito, Tetsuya Takagawa, Hiroyuki Hanai, Hiroshi Araki, Yu Sasaki, Hirotake Sakuraba, Makoto Sasaki, Tadakazu Hisamatsu, Satoshi Motoya, Takayuki Matsumoto, Motoyuki Onodera, Yoh Ishiguro, Hiroshi Nakase, Akira Andoh, Sa
    Inflammatory Bowel Diseases.2022; 28(1): 21.     CrossRef
  • A complicated case of Serratia marcescens catheter-related bloodstream infection misdiagnosed as hypersensitivity reactions to bicarbonate dialysate containing acetate
    Hisato Shima, Takuya Okamoto, Tomoko Inoue, Manabu Tashiro, Yusaku Tanaka, Norimichi Takamatsu, Seiichiro Wariishi, Kazuhiko Kawahara, Kazuyoshi Okada, Jun Minakuchi
    CEN Case Reports.2022; 11(1): 55.     CrossRef
  • Cyanamide-induced oral lichenoid drug reaction: Case report and literature review
    Yurie Akiyama, Yusuke Oomura, Masahiro Okamura, Chiho Hiraga-Kondo, Taiki Suzuki, Kazumichi Sato, Shinichi Takahashi, Takeshi Nomura
    Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.2022; 34(2): 209.     CrossRef
  • 5‐Aminosalicylic acid‐induced pericarditis in pediatric Crohn’s disease
    Yuki Toguchi, Kahoru Fukuoka‐Araki, Kei Matayoshi, Saori Kinjo, Toshifumi Yodoshi
    Pediatrics International.2022;[Epub]     CrossRef
  • Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency
    Hotaka Tamura, Koji Nakashima, Naomi Uchiyama, Souichiro Ogawa, Hiroshi Hatada, Naoki Yoshida, Keisuke Uchida, Yoshinori Ozono, Hiroyuki Tanaka, Koji Yamamto, Hiroshi Kawakami
    Internal Medicine.2022; 61(10): 1503.     CrossRef
  • A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
    Mimari Kanazawa, Keiichi Tominaga, Akira Kanamori, Takanao Tanaka, Satoshi Masuyama, Shoko Watanabe, Keiichiro Abe, Akira Yamamiya, Kenichi Goda, Atsushi Irisawa
    Medicina.2022; 58(2): 276.     CrossRef
  • A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease
    Kevin Cesa, Catherine Cunningham, Tyler Harris, Whitney Sunseri
    Cureus.2022;[Epub]     CrossRef
  • Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
    Yuki Minagawa, Kazuhiko Uchiyama, Tomohisa Takagi, Katsura Mizushima, Kohei Asaeda, Mariko Kajiwara-Kubota, Saori Kashiwagi, Yuma Hotta, Makoto Tanaka, Ken Inoue, Osamu Dohi, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Katada, Kazuhiro Kamada, Takeshi Ishi
    Journal of Clinical Biochemistry and Nutrition.2022; 71(3): 249.     CrossRef
  • Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
    Sakiko Hiraoka, Akiko Fujiwara, Tatsuya Toyokawa, Reiji Higashi, Yuki Moritou, Shinjiro Takagi, Kazuhiro Matsueda, Seiyuu Suzuki, Jiro Miyaike, Toshihiro Inokuchi, Masahiro Takahara, Jun Kato, Hiroyuki Okada
    Journal of Gastroenterology and Hepatology.2021; 36(1): 137.     CrossRef
  • Maternal mesalazine-induced neonatal gastrointestinal bleeding
    Kohichiroh Nii, Kaoru Okazaki, Hitoshi Okada, Toru Kuboi
    BMJ Case Reports.2021; 14(4): e238743.     CrossRef
  • Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
    Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
    Journal of Gastroenterology.2021; 56(6): 489.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • Hypersensitivity reactions to bicarbonate dialysate containing acetate: a case report with literature review
    Yoko Nishiuchi, Hisato Shima, Yoshio Fukata, Tomohiro Tao, Takuya Okamoto, Norimichi Takamatsu, Kazuyoshi Okada, Jun Minakuchi
    CEN Case Reports.2020; 9(3): 243.     CrossRef
  • Anaphylaxis to three humanized antibodies for severe asthma: a case study
    Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito, Kazuhisa Takahashi
    Allergy, Asthma & Clinical Immunology.2020;[Epub]     CrossRef
  • Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report
    Yoshinori Arai, Maiko Ogawa, Fumitsugu Yamane, Natsuki Sumiyoshi, Rikako Arimoto, Yoshitaka Ando, Daisuke Endo, Tatsuya Nakada, Ichiro Sugawara, Hiroshi Yokoyama, Keiko Shimoyama, Hiroko Inomata, Yosuke Kawahara, Masayuki Kato, Seiji Arihiro, Atsushi Hoka
    Clinical Journal of Gastroenterology.2020; 13(6): 1200.     CrossRef
  • Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
    Satohiro Matsumoto, Hirosato Mashima
    Scientific Reports.2020;[Epub]     CrossRef
  • Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis
    Rumiko Tsuboi, Satohiro Matsumoto, Hiroyuki Miyatani, Hirosato Mashima
    Internal Medicine.2019; 58(5): 649.     CrossRef
  • Allergic reactions to small-molecule drugs: Will we move from reaction to prediction?
    Mark F Bonfiglio, David M Weinstein
    American Journal of Health-System Pharmacy.2019; 76(9): 574.     CrossRef
  • 7,713 View
  • 235 Download
  • 28 Web of Science
  • 34 Crossref
Close layer
Case Report
Drug-induced eosinophilic pneumonia in a patient with Crohn's disease: diagnosis and treatment using fraction of exhaled nitric oxide
Jina Yeo, Hyun Sun Woo, Sang Min Lee, Yoon Jae Kim, Kwang An Kwon, Dong Kyun Park, Jung Ho Kim, Kyoung Oh Kim, Jun-Won Chung
Intest Res 2017;15(4):529-534.   Published online October 23, 2017
DOI: https://doi.org/10.5217/ir.2017.15.4.529
AbstractAbstract PDFPubReaderePub

Oral 5-aminosalicylic acid agents (mesalazine and sulfasalazine) and azathioprine are the mainstays of treatment for inflammatory bowel disease. Reports of pulmonary toxicity induced by oral 5-aminosalicylic acid agents or azathioprine in patients with inflammatory bowel disease are very rare; to date, only 38 cases have been reported worldwide. We, herein, report a case involving a 26-year-old man who was diagnosed with eosinophilic pneumonia after using mesalazine and azathioprine for the treatment of Crohn's disease and recovered after treatment. We also found that the fraction of exhaled nitric oxide level was elevated in this patient. After treatment, the fraction of exhaled nitric oxide level decreased and the symptoms improved. The present case shows that fraction of exhaled nitric oxide is related to the disease activity and treatment effectiveness of druginduced eosinophilic pneumonia.

Citations

Citations to this article as recorded by  
  • Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system
    Ashwin Kamath
    Scientific Reports.2025;[Epub]     CrossRef
  • Qualitative and quantitative study of intermolecular weak interactions for aminosalicylic acid isomers by terahertz spectroscopy
    Yuan Tang, Zhi Li, Shan Tu, Yulai She, Yongying Gan
    International Journal of Quantum Chemistry.2022;[Epub]     CrossRef
  • Spontaneous resolution of focal eosinophilic myositis of the adductor pollicis complicated by lung lesions
    Sayuri Yamashita, Hidenaga Kawasumi, Makiko Kimura, Mutsuto Tateishi
    Modern Rheumatology Case Reports.2020; 4(1): 106.     CrossRef
  • lncRNACNN3-206 activates intestinal epithelial cell apoptosis and invasion by sponging miR-212, an implication for Crohn's disease
    Na Li, Rui-Hua Shi
    World Journal of Gastroenterology.2020; 26(5): 478.     CrossRef
  • Expression alteration of long non-coding RNAs and their target genes in the intestinal mucosa of patients with Crohn’s disease
    Na Li, Ruihua Shi
    Clinica Chimica Acta.2019; 494: 14.     CrossRef
  • Mesalazin-induced eosinophilic pneumonia in a 15-year-old boy with ulcerative colitis
    G. N. Yankinа, L. V. Gorlenko, E. V. Loshkova, E. I. Kondratyeva, E. Yu. Tuteva, A. A. Terenteva, V. A. Zhelev, E. V. Mikhalev, T. A. Shemyakinа, T. S. Krivonogova, N. A. Ryzhakova, E. V. Romanova
    Bulletin of Siberian Medicine.2019; 18(3): 245.     CrossRef
  • Oxidative Stress and Effect of Treatment on the Oxidation Product Decomposition Processes in IBD
    Ewa Dudzińska, Magdalena Gryzinska, Katarzyna Ognik, Paulina Gil-Kulik, Janusz Kocki, Vladimir Jakovljevic
    Oxidative Medicine and Cellular Longevity.2018;[Epub]     CrossRef
  • 7,259 View
  • 71 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Original Article
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, Isamu Saida, Toshifumi Hibi
Intest Res 2016;14(1):50-59.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.50
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

The therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients. This study aimed to provide new insight for dose optimization using two doses of pH-dependent release mesalamine for induction of remission of moderately active ulcerative colitis (UC).

Methods

In a multicenter, double-blind, randomized study, 110 patients with moderately active UC were assigned to two groups after treatment with a constant dose of mesalamine. Fifty-five patients were treated with a pH-dependent release formulation of 3.6 or 4.8 g/day for 8 weeks. The primary endpoint was a decrease in the UC disease activity index (UCDAI) adjusted by covariates.

Results

In the full analysis set (n=110), the mean decrease in UCDAI was 3.1 in the 3.6 g/day group and 3.4 in the 4.8 g/day group (P>0.05). In a subgroup analysis, the effectiveness of the 4.8 g/day dose was greater in particular populations, such as those who had been previously treated with a lower dose of mesalamine and those with more severe disease. The safety was comparable between the two groups.

Conclusions

The results suggest that treatment with pH-dependent release mesalamine at either 3.6 or 4.8 g/day was effective and safe for the induction of remission in patients with moderately active UC. However, the patients receiving mesalamine at 2.4 g/day but in whom the therapeutic effect is not sufficient and having more severe symptoms (UCDAI 9-10), benefit from higher doses of mesalamine compared to others.

Citations

Citations to this article as recorded by  
  • Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
    Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kir
    Intestinal Research.2020; 18(4): 355.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
    Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi
    Intestinal Research.2017; 15(3): 368.     CrossRef
  • Remission endpoints in ulcerative colitis: A systematic review
    Maki Jitsumura, Rory Frederick Kokelaar, Dean Anthony Harris
    World Journal of Meta-Analysis.2017; 5(4): 85.     CrossRef
  • Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease
    Celestine Wong, Philip Harris, Lynnette Ferguson
    International Journal of Molecular Sciences.2016; 17(6): 919.     CrossRef
  • What is the real-life maintenance mesalazine dose in ulcerative colitis?
    Alicia Algaba, Iván Guerra, Ana García García de Paredes, María Hernández Tejero, Carlos Ferre, Daniel Bonillo, Lara Aguilera, Antonio López-Sanromán, Fernando Bermejo
    Revista Española de Enfermedades Digestivas.2016;[Epub]     CrossRef
  • 5,900 View
  • 66 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Intest Res : Intestinal Research
© Korean Association for the Study of Intestinal Diseases.
Close layer
TOP